Correlation Between Enanta Pharmaceuticals and Sonoma Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Enanta Pharmaceuticals and Sonoma Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Enanta Pharmaceuticals and Sonoma Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Enanta Pharmaceuticals and Sonoma Pharmaceuticals, you can compare the effects of market volatilities on Enanta Pharmaceuticals and Sonoma Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Enanta Pharmaceuticals with a short position of Sonoma Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Enanta Pharmaceuticals and Sonoma Pharmaceuticals.

Diversification Opportunities for Enanta Pharmaceuticals and Sonoma Pharmaceuticals

-0.19
  Correlation Coefficient

Good diversification

The 3 months correlation between Enanta and Sonoma is -0.19. Overlapping area represents the amount of risk that can be diversified away by holding Enanta Pharmaceuticals and Sonoma Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Sonoma Pharmaceuticals and Enanta Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Enanta Pharmaceuticals are associated (or correlated) with Sonoma Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Sonoma Pharmaceuticals has no effect on the direction of Enanta Pharmaceuticals i.e., Enanta Pharmaceuticals and Sonoma Pharmaceuticals go up and down completely randomly.

Pair Corralation between Enanta Pharmaceuticals and Sonoma Pharmaceuticals

Given the investment horizon of 90 days Enanta Pharmaceuticals is expected to generate 2.41 times less return on investment than Sonoma Pharmaceuticals. But when comparing it to its historical volatility, Enanta Pharmaceuticals is 1.39 times less risky than Sonoma Pharmaceuticals. It trades about 0.03 of its potential returns per unit of risk. Sonoma Pharmaceuticals is currently generating about 0.04 of returns per unit of risk over similar time horizon. If you would invest  275.00  in Sonoma Pharmaceuticals on December 28, 2024 and sell it today you would earn a total of  13.00  from holding Sonoma Pharmaceuticals or generate 4.73% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Enanta Pharmaceuticals  vs.  Sonoma Pharmaceuticals

 Performance 
       Timeline  
Enanta Pharmaceuticals 

Risk-Adjusted Performance

Weak

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Enanta Pharmaceuticals are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unsteady basic indicators, Enanta Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in April 2025.
Sonoma Pharmaceuticals 

Risk-Adjusted Performance

Insignificant

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Sonoma Pharmaceuticals are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite somewhat inconsistent basic indicators, Sonoma Pharmaceuticals sustained solid returns over the last few months and may actually be approaching a breakup point.

Enanta Pharmaceuticals and Sonoma Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Enanta Pharmaceuticals and Sonoma Pharmaceuticals

The main advantage of trading using opposite Enanta Pharmaceuticals and Sonoma Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Enanta Pharmaceuticals position performs unexpectedly, Sonoma Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sonoma Pharmaceuticals will offset losses from the drop in Sonoma Pharmaceuticals' long position.
The idea behind Enanta Pharmaceuticals and Sonoma Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Other Complementary Tools

Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance